Mavalon Therapeutics
Mavalon is developing drugs to stop the progression of Parkinson's disease.
Funding reportedLast round: Seed
What company datasets say Mavalon Therapeutics raised
Funding, as reported
Reported in all9.5Min the source's currency
Rounds1
Last roundSeed
Last round dateOct 2016
Biotechnology in the same market
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Mavalon Therapeutics in front of investors. Or tell us what we have wrong.